Physician profile
David E Steidley
NPI 1356325690
$57,371.42
in general payments reported to CMS, 2019-2025
11 companies · $43K in 2025
The $43K reported for 2025 was more than what 92% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $100 · 2021: $1,639 · 2022: $48.52 · 2023: $516 · 2024: $12K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Food and Beverage: $2,639 · Travel and Lodging: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,790.88 |
| Food and Beverage | $2,638.75 |
| Travel and Lodging | $1,782.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $50,590.88 | 2024-2025 | Ultomiris |
| One Lambda, INC. | $2,464.23 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,330.80 | 2019-2025 | Lifevest |
| Abbott Laboratories | $685.51 | 2022-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $274.61 | 2024-2025 | Impella |
| Medtronic Vascular, INC. | $204.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2025 | |
| Cvrx, INC. | $186.25 | 2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $149.40 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $146.38 | 2025 | Attruby |
| Zoll Respicardia, INC. | $138.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Steidley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.